KalVista (KALV) Climbs 30% After Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

Visit StreetInsider.com at http://www.streetinsider.com/Momentum+Movers/KalVista+%28KALV%29+Climbs+30%25+After+Phase+3+KONFIDENT+Trial+Meets+All+Endpoints+for+Sebetralstat+as+First+Oral+On-demand+Therapy+for+Hereditary+Angioedema/22761137.html for the full story.